The EASAC FEAM Statement on Vaccination and beyond

Jos WM van der Meer

MD PhD FRCP(Lon) FRCP(Edin) FIDSA FESCMID MAE Emeritus Professor of Medicine Radboud University Immediate past President EASAC





Vaccination




Considered one of the great success stories in medical sciences



Edward Jenner vaccinating against smallpox









Elvis Presley receives a polio vaccination from Dr Lena Baumgartner and Dr Harold Fuerst at CBS studio in NY, Oct 28, 1956







EC Roadmap 'Strengthened cooperation against vaccine preventable disease'



- Public consultation in Early 2018
- EASAC and FEAM were not happy with the format of the consultation and decided to formulate a commentary.









Vaccination in Europe

An EASAC and FEAM commentary on the EC Roadmap 'Strengthened cooperation against vaccine preventable diseases'

EASAC FEAM commentary

- The commentary was considered a necessary first step
- More exploration and scoping of the problem at the different levels and in the different areas was felt necessary

in the state of th

• To that end 2 conferences in 2018:

- Scientific and social aspects (A'dam Oct 2018)

- Science policy interface (FEAM Forum Brussels Nov 2018)





EASAC FEAM commentary

in the state

- Vaccine coverage
- Health impact of vaccines
- Quality of vaccines
- Vaccine rejection and hesitancy
- Vaccine availability
- New vaccine development





Since then...



• EC adopted a proposal for a Council Recommendation and Communication on Strengthened Cooperation against Vaccine Preventable Diseases (April 2018):

tackling vaccine hesitancy and improving vaccination coverage;
sustainable vaccination policies in the EU;

3) EU co-ordination and contribution to global health.

State of Vaccine Confidence in the EU 2018







Programme Conference Amsterdam October 2018



- Welcome *Prof. Wim van Saarloos (KNAW)*
- The EASAC-FEAM statement *Prof. Jos van der Meer (EASAC)*
- Vaccine coverage in the EU *Dr. Piotr Kramarz (ECDC)*
- The tailoring immunisation programme *Dr. Katrine Bach Habersaat* (WHO)
- Not all vaccines are equal *Prof. Jaap van Dissel (CIB RIVM)*
- The effects of vaccines on innate immunity *Prof. Mihai Netea* (Radboud UMC)
- How to improve the flu vaccine *Prof. Ron Fouchier (Erasmus MC)*
- Dealing with vaccine hesitancy and rejection *Prof. Tara Smith (Kent State Univ)*
- Vaccine discussion on the internet *Prof. Piek Vossen (VU University)*
- The way ahead *Prof. George Griffin (FEAM)*









Rijksinstituut voor Volksgezondheid en Milieu Ministerie van Volksgezondheid, Welzijn en Sport





Vaccination in Europe

An EASAC and FEAM commentary on the EC Roadmap 'Strengthened cooperation against vaccine preventable diseases'

EASAC & FEAM Vaccination Recommendations (1)

1. Investigate the reasons for low and decreasing vaccine uptake at the level of EU Member States in order to develop tailor-made interventions. Make use of the WHO TIPS programme.

It is a heterogeneous multi-faceted problem at the level of the members states. Where are the obstacles? What are the experiences with the TIPS programme?

in the second second

European Academies Calebra C



At the Amsterdam meeting



- It is a member state problem
- The TIPS approach is worthwhile, but amount of work and costs are unclear
- Yet, such data are badly needed
- Explanations for decline in vaccine uptake may be unexpected



Katrine Bach-Habersaat





EASAC & FEAM Vaccination Recommendations (2)



2. Develop and implement a European vaccination card and registry. Do not give normalisation of vaccine programmes (i.e., the choice of dose and timing) among different countries a high priority.

The former is OK

The latter is considered a waste of time and money with a high risk to fail

European Academies Calebra Sac Science Advisory Council



At the Amsterdam meeting:

- In every country has an advisory committee (NITAG); ECDC hopes to strengthen the coordination and harmonisation.
- The IMI-funded ADVANCE project aims to make a major contribution to the vaccine debate in the context of digital health, for example a full riskbenefit assessment based on real world and real time data.



- Indered Street

Piotr Kramarz





EASAC & FEAM Vaccination Recommendations (3)

3. Recognize that not all vaccines in the vaccination programmes are of equal relevance for public health and for individual protection. Make priorities in these programmes.

At population level: diphteria, polio vaccines At individual level: tetanus, rabies vaccines At both levels: meningococcal vaccines

European Academies





Jaap van Dissel



in the state

EASAC & FEAM Vaccination Recommendations (4)



4. Recognize that not all vaccines are of optimal general quality in terms of efficacy and side effects

examples: influenza vaccine pertussis vaccine





At the Amsterdam meeting

- The problems with the quality flu vaccine are obvious:
 - Poor antibody response (in elderly and sick persons)
 - Poor protection because of bad fit to the prevalent strains

Measures:

- higher dose to poor responders
- quadrivalent vaccine (Type B)
- Other ways of application
- Better adjuvants
- Better prediction of next year's strains (big data, antigenic cartography)
- Aiming at other antigens (e.g., broad acting vaccine)



Ron Fouchier

European Academies

Science Advisory Council



EASAC & FEAM Vaccination Recommendations (5)

5. To deal with the problem of vaccine rejection and hesitance, realise that the approach to vaccine hesitant, vaccine resistant and vaccine rejecting groups is different. With the help of social scientists, develop strategies to enhance vaccine uptake in vaccine hesitant and vaccine resistant individuals.

in the second se







Tara Smith



Open Forum Infectious Diseases

REVIEW ARTICLE



Vaccine Rejection and Hesitancy: A Review and Call

to Action

Tara C. Smith¹ ¹College of Public Health, Kent State University, Ohio

'the positive narrative' 'no jab, no play'









Piek Vossen



- Scanning the dispersed information on the internet
- Much information on the internet, little communication; a post ≠ a debate
- Anti vaccine lobby and professional and governmental information are in separate bubbles

European Academies Calebra C



EASAC & FEAM Vaccination Recommendations (6)

6. Develop a monitoring system for vaccine shortage and stimulate vaccine production by industry at the European level ensuring safety and quality of manufacturing.

in the state





EASAC & FEAM Vaccination Recommendations (7)



7. Revisit the BCG vaccination programmes in childhood: the vaccine does not induce long-lasting protection against tuberculosis and there is a serious worldwide shortage of the vaccine.

specific protection vs trained immunity

European Academies

Science Advisory Council





Mihai Netea

EASAC & FEAM Vaccination Recommendations (8)



8. Investigate and optimise vaccination schedules for those vaccines for which there is a shortage.

e.g., intracutaneous injection







EASAC & FEAM Vaccination Recommendations (9)



9. Develop a priority list of those vaccines that need improvement

antigenic quality adjuvant quality





EASAC & FEAM Vaccination Recommendations (10)



10. Develop a priority list of vaccines for which there is high need

This could provide the basis for a European public private partnership in vaccine discovery and development

European Academies Calebra C








Vaccination in Europe


An EASAC and FEAM commentary on the EC Roadmap 'Strengthened cooperation against vaccine preventable diseases'



Common concerns about risks and benefits of vaccination in Europe







Source: The State of Vaccine Confidence (2016) project.



